Media stories about Dova Pharmaceuticals (NASDAQ:DOVA) have been trending somewhat positive this week, Accern Sentiment reports. Accern scores the sentiment of press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Dova Pharmaceuticals earned a media sentiment score of 0.21 on Accern’s scale. Accern also gave news stories about the company an impact score of 47.8862036212958 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

A number of analysts have issued reports on the company. Jefferies Group LLC assumed coverage on Dova Pharmaceuticals in a report on Monday, July 24th. They set a “buy” rating and a $30.00 price target for the company. J P Morgan Chase & Co assumed coverage on Dova Pharmaceuticals in a report on Monday, July 24th. They set an “overweight” rating and a $35.00 price target for the company. Finally, Leerink Swann raised Dova Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $32.00 price target for the company in a report on Tuesday, September 26th.

Shares of Dova Pharmaceuticals (NASDAQ DOVA) traded up 2.85% during mid-day trading on Friday, reaching $27.39. The company’s stock had a trading volume of 18,880 shares. Dova Pharmaceuticals has a 52 week low of $18.18 and a 52 week high of $28.24. The firm has a 50-day moving average of $25.38 and a 200-day moving average of $24.52. The firm’s market capitalization is $702.61 million.

Dova Pharmaceuticals (NASDAQ:DOVA) last issued its quarterly earnings results on Thursday, August 10th. The company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.08). Equities research analysts forecast that Dova Pharmaceuticals will post ($1.40) earnings per share for the current fiscal year.

In related news, Director Steven M. Goldman purchased 20,169 shares of Dova Pharmaceuticals stock in a transaction dated Tuesday, August 15th. The shares were acquired at an average price of $22.23 per share, with a total value of $448,356.87. Following the completion of the transaction, the director now owns 81,158 shares of the company’s stock, valued at approximately $1,804,142.34. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Paul B. Manning purchased 25,870 shares of Dova Pharmaceuticals stock in a transaction dated Wednesday, August 16th. The shares were bought at an average cost of $22.30 per share, for a total transaction of $576,901.00. The disclosure for this purchase can be found here.

TRADEMARK VIOLATION WARNING: This report was originally published by Watch List News and is owned by of Watch List News. If you are reading this report on another site, it was illegally stolen and republished in violation of United States and international copyright laws. The original version of this report can be read at

About Dova Pharmaceuticals

Dova Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is focused on acquiring, developing and commercializing drug candidates. The Company’s initial focus is on thrombocytopenia, a disorder characterized by a low blood platelet count. The Company is developing avatrombopag for treatment of thrombocytopenia in patients with chronic liver disease (CLD).

Insider Buying and Selling by Quarter for Dova Pharmaceuticals (NASDAQ:DOVA)

Receive News & Ratings for Dova Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.